For instance, a recent phase I/II study evaluated the efficacy of MBG453 individually and in mixture with Spartalizumab (anti-PD-1 mAb) in patients with advanced malignancies, including CRC. This evidence concerns the gene PDCD1 and colorectal carcinoma.